rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Peter A. Thompson

Director and 10% owner

Company insider

Files Form 4 as: Director and 10% owner, Aspen Neuroscience; Director, Sionna Therapeutics; Director and 10% owner, ARS Pharmaceuticals; Director and 10% owner, Corvus Pharmaceuticals; Director and 10% owner, Edgewise Therapeutics; Director and 10% owner, Alpine Immune Sciences; Director and 10% owner, Decibel Therapeutics; Director and 10% owner, Janux Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
356
Buys
43
Sells
39
Bought
$229.0M
Sold
$191.8M
Companies
16
Companies where not an officer
14
First trade
18 Oct 2006
Last trade
2 Nov 2026
Last filed
4 Nov 2026

Companies traded

Where they are an officer
Response BiomedicalDirector, Officer, 10% owner · last 29 Nov 20161 buy · 0 sells
Trubion PharmaceuticalsDirector, Officer · last 27 Aug 20092 buys · 0 sells
Everywhere else they filed: board seats, 10% stakes, other companies
ASPE Aspen NeuroscienceDirector, 10% owner · Biotechnology · last 2 Nov 20261 buy · 0 sells
SION Sionna TherapeuticsDirector · Biotechnology · last 7 Jul 20261 buy · 20 sells
SPRY ARS PharmaceuticalsDirector, 10% owner · Pharmaceuticals · last 24 Jun 20262 buys · 4 sells
CRVS Corvus PharmaceuticalsDirector, 10% owner · Biotechnology · last 11 Jun 202619 buys · 2 sells
EWTX Edgewise TherapeuticsDirector, 10% owner · Biotechnology · last 5 Jun 20265 buys · 0 sells
Alpine Immune SciencesDirector, 10% owner · last 20 May 20242 buys · 3 sells
Decibel TherapeuticsDirector, 10% owner · last 17 Jun 20221 buy · 0 sells
JANX Janux TherapeuticsDirector, 10% owner · Biotechnology · last 14 Jun 20221 buy · 3 sells
PMVP PMV PharmaceuticalsDirector, 10% owner · Biotechnology · last 9 Jun 20211 buy · 0 sells
Prevail TherapeuticsDirector, 10% owner · last 22 Jan 20211 buy · 0 sells
SynthorxDirector, 10% owner · last 23 Jan 20201 buy · 0 sells
Adaptimmune TherapeuticsDirector · last 6 Jun 20184 buys · 7 sells

14 of 16 companies.

Activity over time

1 Dec 2024 – 1 Nov 2026
50Dec 24Jun 25Dec 25May 26Nov 26

Buys above the line, sells below, each month. 1 lines have no legible date and are left out.

Every trade

TradedCompanyWhatAmount
2 Nov 2026filed 4 Nov 2026ASPE Aspen NeuroscienceBiotechnologySEC FORM 4 Code C—196,541filing
2 Nov 2026filed 4 Nov 2026ASPE Aspen Neuroscienceoption or derivative · BiotechnologySEC FORM 4 Code C—625,743 at $0.00filing
2 Nov 2026filed 4 Nov 2026ASPE Aspen Neuroscienceoption or derivative · BiotechnologySEC FORM 4 Code C—507,119 at $0.00filing
2 Nov 2026filed 4 Nov 2026ASPE Aspen NeuroscienceBiotechnologySEC FORM 4 Code C—642,745filing
2 Nov 2026filed 4 Nov 2026ASPE Aspen NeuroscienceBiotechnologySEC FORM 4 Code C—616,984filing
2 Nov 2026filed 4 Nov 2026ASPE Aspen NeuroscienceBiotechnologySEC FORM 4 Code C—625,743filing
2 Nov 2026filed 4 Nov 2026ASPE Aspen NeuroscienceBiotechnologySEC FORM 4 Code C—507,119filing
2 Nov 2026filed 4 Nov 2026ASPE Aspen NeuroscienceBiotechnologySEC FORM 4 Bought$15.0M1,000,000 at $15.00filing
2 Nov 2026filed 4 Nov 2026ASPE Aspen Neuroscienceoption or derivative · BiotechnologySEC FORM 4 Code C—196,541 at $0.00filing
2 Nov 2026filed 4 Nov 2026ASPE Aspen Neuroscienceoption or derivative · BiotechnologySEC FORM 4 Code C—642,745 at $0.00filing
2 Nov 2026filed 4 Nov 2026ASPE Aspen Neuroscienceoption or derivative · BiotechnologySEC FORM 4 Code C—616,984 at $0.00filing
7 Jul 2026filed 9 Jul 2026SION Sionna TherapeuticsBiotechnologySEC FORM 4 Sold$3.9M85,918 at $44.86filing
7 Jul 2026filed 9 Jul 2026SION Sionna TherapeuticsBiotechnologySEC FORM 4 Sold$3.9M85,918 at $44.86filing
30 Jun 2026filed 2 Jul 2026SION Sionna TherapeuticsBiotechnologySEC FORM 4 Sold$5.3M115,844 at $45.50filing
30 Jun 2026filed 2 Jul 2026SION Sionna TherapeuticsBiotechnologySEC FORM 4 Sold$5.3M115,844 at $45.50filing
24 Jun 2026filed 26 Jun 2026SPRY ARS Pharmaceuticalsoption or derivative · PharmaceuticalsSEC FORM 4 Code A—30,000 at $0.00filing
24 Jun 2026filed 26 Jun 2026SPRY ARS Pharmaceuticalsoption or derivative · PharmaceuticalsSEC FORM 4 Code A—30,000 at $0.00filing
17 Jun 2026filed 18 Jun 2026SION Sionna Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—17,340 at $0.00filing
17 Jun 2026filed 18 Jun 2026SION Sionna Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—17,340 at $0.00filing
11 Jun 2026filed 15 Jun 2026CRVS Corvus Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—15,000 at $0.00filing

News

Aspen Neuroscience (ASPE) raises $140.6 million in Nasdaq IPO at $15ASPE · 247wallst.com · 30 Oct 2026

0 headlines in the last 90 days name Peter A. Thompson; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.

Sectors

Health Care59
Not placed23

Buys in green, sells in red, by the company’s sector.

Related people

ARCH Venture Fund X, L.P.10% owner · Also traded ASPE in the last 90 days
ARCH Venture Partners XIV, L.P.10% owner · Also traded ASPE in the last 90 days
ORBIMED ADVISORS LLCDirector and 10% owner · Also traded ASPE in the last 90 days
RA CAPITAL MANAGEMENT, L.P.Director and 10% owner · Also traded SION in the last 90 days
Joanne M. DonovanCmo · Also traded EWTX in the last 90 days
Alan J. RussellChief Scientific Officer · Also traded EWTX in the last 90 days
Behrad DerakhshanChief Business Officer · Also traded EWTX in the last 90 days
John R. MooreGeneral Counsel · Also traded EWTX in the last 90 days